Lupin gets nod from USFDA for generic Zorvolexv Capsules

06 Dec 2016 Evaluate

Lupin’s US subsidiary, Lupin Pharmaceuticals, Inc, has received tentative approval for its Diclofenac Capsules USP, 18 mg and 35 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Iroko Pharmaceuticals LLC's Zorvolex Capsules 18 mg and 35 mg.

Lupin's Diclofenac Capsules USP, 18 mg and 35 mg are the AB rated generic equivalent of Iroko Pharmaceuticals LLC's Zorvolex Capsules 18 mg and 35 mg. It is indicated for management of mild to moderate acute pain and management of osteoarthritis pain. Zorvolex Capsules had US sales of USD 39.6 million as per IMS MAT September 2016.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×